Integrum AB (publ) (STO:INTEG.B)
8.29
-0.04 (-0.48%)
At close: Apr 27, 2026
Integrum AB Revenue
Integrum AB had revenue of 21.31M SEK in the quarter ending January 31, 2026, a decrease of -17.11%. This brings the company's revenue in the last twelve months to 98.18M, up 0.90% year-over-year. In the fiscal year ending April 30, 2025, Integrum AB had annual revenue of 97.52M, down -11.71%.
Revenue (ttm)
98.18M
Revenue Growth
+0.90%
P/S Ratio
2.20
Revenue / Employee
2.81M
Employees
35
Market Cap
216.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 97.52M | -12.94M | -11.71% |
| Apr 30, 2024 | 110.46M | 32.91M | 42.44% |
| Apr 30, 2023 | 77.55M | 16.72M | 27.50% |
| Apr 30, 2022 | 60.82M | 17.02M | 38.87% |
| Apr 30, 2021 | 43.80M | 16.19M | 58.62% |
| Apr 30, 2020 | Pro | Pro | Pro |
| Apr 30, 2019 | Pro | Pro | Pro |
| Apr 30, 2018 | Pro | Pro | Pro |
| Apr 30, 2017 | Pro | Pro | Pro |
| Apr 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Promimic AB | 51.06M |
| Nosa Plugs AB | 23.91M |
| Ortoma AB | 67.27M |
| Clinical Laserthermia Systems AB | 17.49M |
| BrainCool AB | 38.69M |
| Boule Diagnostics AB | 489.69M |
| Acarix AB | 7.36M |
| Scandinavian Real Heart AB (Publ) | 153.10K |
Integrum AB News
- 5 months ago - Integrum AB Transcript: Q2 25/26 - Transcripts
- 8 months ago - Integrum AB Transcript: Q1 25/26 - Transcripts
- 1 year ago - Integrum AB Transcript: Q3 24/25 - Transcripts
- 1 year ago - Integrum AB Transcript: Q2 24/25 - Transcripts
- 1 year ago - Integrum AB Transcript: Investor Update - Transcripts
- 1 year ago - Integrum AB Transcript: Q1 24/25 - Transcripts
- 2 years ago - Integrum AB Transcript: Q4 23/24 - Transcripts
- 2 years ago - Integrum AB Transcript: Q3 23/24 - Transcripts